Kornimate/medical-research-clean huggingface dataset:
a prospective clinical study of transthoracic single-hole assisted laparoscopic radical gastrectomy for siewert ⅱ aeg

Conditions: Esophagogastric Junction Adenocarcinoma; Siewert Type II Adenocarcinoma of Esophagogastric Junction

Summary: objective: to evaluate the safety, feasibility and clinical efficacy of transthoracic single-hole assisted laparoscopic radical gastrectomy for siewert type ⅱ adenocarcinoma of esophagogastric junction. methods: a prospective, single-center, one-arm study will be performed. patients who have been diagnosed with siewert type ⅱ esophagogastric junction adenocarcinoma and meet the eligibility criteria will be included in the study and undergo the transthoracic single-hole assisted laparoscopic radical gastrectomy. the data of preoperative, intraoperative, postoperative and follow-up will be recorded and analyzed. primary study endpoints: the incidences of early postoperative complications and mortality. the secondary study endpoints:(1) surgery and oncology indicators ;(2) early postoperative recovery information ;(3) 3-year disease-free survival and overall survival rate;(4) 5-year disease-free survival and overall survival.

1. surgery and oncology indicators,such as length of operation, intraoperative blood loss, transit thoracotomy or laparotomy rate, length of proximal tumor from esophageal resection margin, number of mediastinal lymph node dissections and the positive, number of abdominal lymph node dissections and the positive, tumor type and pathological stage, etc.; 2. early postoperative recovery information ,such as time of first exhaust and defecation, time of leaving the bed, time of recovery of full and half-flow diet, time of removal of chest drainage tube, time of postoperative hospitalization, etc.

Eligibility criteria:
inclusion criteria: * informed consent of patients; * the tumor invaded the anatomy esophagogastric junction (egj), with the tumor center located at the egj line from 1cm above to 2cm below(siewertⅱ). * the endoscopic biopsy was diagnosed with adenocarcinoma; * preoperative clinical staging was ct1-4ananym0 * no distant metastasis and invasion of surrounding organs were found; * ecog score ranged from 0 to 1; * asa score ranged from i to iii. exclusion criteria: * pregnant or lactating women * have a severe mental illness * history of esophagectomy and gastrectomy (including emr / esd for gastric and esophageal cancer) * history of other malignant tumors within 5 years * history of unstable angina pectoris or myocardial infarction within 6 months * fev1% of pulmonary function test was less than 50% of expected value * history of cerebral infarction or cerebral hemorrhage within 6 months * have severe liver and kidney damage
plasma and urine tmao formation and changes to oxidized ldl after ingestion of different amounts of egg

Conditions: Biomarkers of Cardiovascular Disease

Summary: eggs contain an essential nutrient called choline and adequate levels of choline are required for good health. studies in mice have demonstrated that high levels of choline may increase risk of heart disease through a process that involves the breakdown of choline by gut bacteria. previous research did not show that human consumption of eggs increases risk of heart disease. this study is designed to investigate whether the number of eggs in the diet affects blood and urine markers for heart disease.

diets low in choline have adverse health consequences, while observations in humans and experiments in mouse models suggest that a diet containing too much choline or phosphatidylcholine may activate inflammatory pathways and increase cardiovascular disease risk through bacterial conversion of choline to trimethylamine (tma) and its subsequent oxidation to trimethylamine n-oxide (tmao) in the liver. what is unclear is whether choline and phosphatidylcholine in eggs is a source of tmao formation, and if so how many eggs must be eaten before enough tmao is generated to cause increased oxidized ldl (a biomarker for atherosclerosis mechanisms). we hypothesize that tmao will only be formed from eggs when very large quantities are ingested and that tmao formation will vary greatly between individuals for any given dietary exposure. this variability will be determined by 1) the dose at which dietary choline or phosphatidylcholine exceeds the absorptive capacity of the volunteer's small intestine and therefore spills into large intestine where gut bacteria have access to it and 2) the bacterial populations that constitute the volunteer's microbiome.

Eligibility criteria:
inclusion criteria: * healthy * non-smoker * body mass index between 20 to 39 kg/m² exclusion criteria: * history of chronic system disease/s (e.g., hepatic, renal, cardiovascular, intestinal) * diabetes controlled by insulin * alcohol or illegal drug misuse/abuse * use of antibiotics or choline-containing supplements within three months of study * allergies to soy, eggs, wheat or other food * use of drugs or medications known to alter liver metabolism, cardiovascular and/or kidney function * abnormal physical examination or abnormal clinical laboratory values * pregnancy * unusual dietary habits
upper extremity robot-assisted therapy in stroke patients

Conditions: Stroke; Upper Extremity

Summary: upper extremity hemiparesis is one of the most common symptoms after stroke. robot-assisted therapies have been used as an approach to rehabilitation of upper extremity hemiplegia in recent years. robot-assisted therapy is an approach to post-stroke rehabilitation that uses robotic devices to provide motor or task-oriented training to patients. when the literature is examined, there are studies showing that robot-assisted therapies are similar or superior to conventional methods. in order to provide the most effective rehabilitation approach in upper extremity robots, it is suggested that it may be more accurate to consider the robotic device as a training platform consisting of various therapeutic techniques and principles, not as a tool alone. a robotic system will be used to overcome the disadvantages of the existing robotic systems in the literature such as not providing support to the patient at the time of need, not providing fluidity in shoulder movements by not taking into account the scapulohumeral rhythm in upper extremity movements, long installation times, and ignoring task-oriented training. the system to be used is a self-aligning exoskeleton system for robot-assisted upper extremity rehabilitation. the system provides safe and versatile rehabilitation at increasing intensity and also allows for objective assessments. the aim of this clinical study was to evaluate the efficacy of robot-assisted upper limb rehabilitation in stroke patients.


Eligibility criteria:
inclusion criteria: * spasticity of the upper extremity muscles is 2 or less according to the modified ashworth scale * stroke patients with a mini mental state examination score of 24 and above will be included in the study exclusion criteria: * have a neurological disease other than stroke that may affect upper extremity movements * surgery or botox application for upper extremity spasticity in the last 6 months * history of upper extremity fracture or surgery * attending another rehabilitation program * individuals who do not agree to participate in the study and do not give written informed consent will be excluded from the study.

Keywords: stroke robot-assisted therapies upper extremity exoskeleton robot motor performance
study to evaluate the long-term safety and efficacy of elagolix in adults with moderate to severe endometriosis-associated pain

Conditions: Endometriosis

Summary: a randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in pre-menopausal women.

this is a phase 3 multicenter, double blind randomized study to assess the continued safety and efficacy of the 150 mg once daily (qd) and 200 mg twice daily (bid) doses of elagolix in premenopausal women with moderate to severe endometriosis-associated pain who completed the 6 month treatment period in the pivotal study m12-665 (nct01620528). the study consists of 2 periods: a 6 month treatment period and a post treatment follow-up period of up to 12 months. participants who received elagolix in the pivotal study who met all entry criteria continued to receive the same dose, either elagolix 150 mg qd or elagolix 200 mg bid for up to an additional 6 months in this extension study; participants who received placebo in the pivotal study were randomized in a 1:1 ratio to receive either elagolix 150 mg qd or elagolix 200 mg bid for up to 6 months. an electronic diary will be used to collect endometriosis-associated pain, uterine bleeding, and analgesic medication use for endometriosis associated pain on a daily basis. all participants who prematurely discontinued treatment (unless pregnant or elected surgery for endometriosis) or completed the 6-month treatment period in this extension study were to enter the post-treatment follow-up (ptfu) period within this study for up to 12 months.

Eligibility criteria:
inclusion criteria: * completed the 6 month treatment period in pivotal study m12-665 (nct01620528) * agrees to use required birth control methods during the study through month 6 of the post-treatment follow-up period exclusion criteria: * clinically significant gynecological condition * bone mineral density (bmd) loss greater than or equal to 8 percent in the spine, femoral neck or total hip * plans to become pregnant in the next 18 months

Keywords: endometriosis associated pain elagolix gonadotropin-releasing hormone antagonist dysmenorrhea (dys) non-menstrual pelvic pain (nmpp)
calcium balance studies in children with ckd and on dialysis

Conditions: Chronic Kidney Disease Mineral and Bone Disorder

Summary: this is a novel, non-invasive method of assessing ca balance by natural ca isotope fractionation.

detailed description and study protocol will be available to individuals on request.

Eligibility criteria:
i - for healthy children inclusion criteria * all children \<18 years * normal renal function (egfr 90-120ml/min/1.73m2 \[calculated by schwartz formula\] in children \>1 year and serum creatinine \<35μmol/l in children \<1 year) * weight, height and bmi within 2 sd of normal using who growth charts in order to make this study as 'real-life' as possible, free-living uk children on their usual diet and dietary supplementation (including ca and vit d), if any, will be included, but analysis will account for medication doses and blood levels. exclusion criteria * pre-existing bone disease - inherited or acquired * fractures in the preceding 6 months * glucocorticoid therapy in the preceding year, or a lifetime cumulative steroid exposure ≥6 months * bisphosphonate therapy at any time in the past * any acute illness in the preceding 2 weeks (when the child is unable to maintain their usual diet or has bed rest) ii - for ckd and dialysis children inclusion criteria * children of all ages with an egfr \<60ml/min/1.73m2, including those on dialysis. exclusion criteria * as listed above for healthy children.

Keywords: ckd dialysis calcium mineral and bone disorder (mbd) calcification dxa peripheral quantitative ct scan (pqct)
strain vs. left ventricular ejection fraction-based cardiotoxicity prevention in breast cancer

Conditions: Cardiotoxicity; Breast Cancer; Prevention; Adjuvant; Trastuzumab

Summary: comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab.

despite the left ventricular global longitudinal strain (gls) enables early prediction of trastuzumab-related cardiomyopathy, its clinical application has been hampered due to the lack of appropriate evaluation and treatment strategies. therefore, we aimed to evaluate the effect of early intervention strategy (gls-based cardiotoxicity monitoring and administration of candesartan) by comparing with conventional intervention strategy (left ventricular ejection fraction-based cardiotoxicity monitoring and administration of candesartan) in breast cancer patients who treated with adjuvant trastuzumab.

Eligibility criteria:
inclusion criteria: * female aged ≥ 18 years * pathologically confirmed her2-positive breast cancer * adjuvant treatment plan comprises at least 12 cycles of trastuzumab * baseline echocardiogram should be performed before starting trastuzumab * cumulative anthracycline dose ≤ 300mg/m2 * written informed consent to participate in the study exclusion criteria: * history of hypersensitivity or alllergic reaction to the study medication * metastatic breast cancer * treatment with angiotensin converting enzyme(ace) inhibitor , angiotensin receptor blocker (arb), beta-blocking agents, or diuretics * patients with nci/ctcae grade ≥ 2 congestive heart failure, myocardial infarction, symptomatic left ventricular systolic dysfunction, heart's valve disease (≥ moderate), arrhythmias (grade ≥ 3) \< 12 months before enrollment * pregnancy or breast feeding * baseline systolic pressure \< 90mmhg * cumulative anthracycline dose \> 300mg/m2 * serious concurrent illness
effectiveness of home-based exercise in quality of life and physical fitness in older woman in breast cancer treatment

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate the effectiveness of home exercise on quality of life and physical fitness of elderly women with breast cancer patients undergoing cancer treatment.

cancer has excelled as a leading cause of mortality. it is particularly serious in the elderly due to increased risk of functional impairment and present comorbidities. the physical exercise appears as a promising intervention in the various stages of the treatment, mitigating the adverse effects in short- and long-term the oncologic treatment. its regular practice after a diagnosis of breast cancer is associated with 40 % to 50 % lower rates of mortality. produces metabolic and morphological changes that may make it an important option in the treatment, prevention, and recovery process of these patients. in this context the present study aims to verify the effectiveness of home exercise on quality of life and physical fitness of elderly undergoing treatment for breast cancer. this study it's a randomized clinical trial. data will be collected at the department of oncology at the professor fernando figueira integral medicine institute (imip), which serves patients in the public health system (sus) from the metropolitan area of recife, state of pernambuco. will be held from march to december 2015. will be studied elderly diagnosed with breast cancer undergoing treatment in the adult oncology service of imip. for the analysis of means and frequencies, the investigators intend to use descriptive statistics and the results will be displayed in graphs and tables. for inferential statistical analysis, the investigators intend to use the student's t test, or the mann - whitney test, according to the normality of the sample. for categorical variables, contingency tables are constructed of type 2x2. chi-square tests of association with yates correction and fisher's exact test will be used. the risk ratio (rr) will be calculated as a measure of the relative risk of different outcomes according to the realization of one or another approach to exercise and control group. the software stata 12.0 will be used for data processing and will be accepted at p \< 0,05. the project meets the requirements of the national board of health and was approved by the imip research ethics committee. patients who agree to sign the instrument of consent will be included in the study.

Eligibility criteria:
inclusion criteria: * breast cancer diagnosis with stage i or ii; * being in treatment for breast cancer (chemotherapy; radiotherapy and / or hormone therapy). exclusion criteria: * absolute contraindication for physical exercises; * severe depression diagnosis using the geriatric depression scale; * malnutrition (wasting grades i, ii and iii), detected by body mass index (bmi), according to the who criteria.

Keywords: breast cancer elderly quality of life exercise
vitamin a and d intake in pregnancy, infant supplementation and asthma development

Conditions: Asthma in Children

Summary: the objective of this study is to investigate if maternal intake of vitamins a and d from food and dietary supplements during pregnancy, and infant supplementation with these vitamins, are associated with development of asthma in the offspring.

this study was conducted as part of the research project "causal pathways for asthma" funded by the norwegian research council (2013-2017). the overall objective was to study if different pregnancy and early life exposures affect the risk of asthma and allergic diseases in children, and if these exposures exert their effects through epigenetic mechanisms, more specifically dna methylation. for this project, including the current study, existing data from the norwegian mother and child study (moba file version 9, 115 398 children and 95 248 mothers) were linked with the medical birth registry of norway and the norwegian prescription database. the moba study recruited pregnant women between 1999 and 2008, at approximately 18 weeks of gestation. beginning 2002, women completed a food frequency questionnaire about dietary intake (food and supplements) in pregnancy. a panel of maternal plasma biomarkers, including plasma retinol and 25-hydroxyvitamin d2 and d3, was available for a random sample of around 3,000 women who gave birth in 2002 and 2003.

Eligibility criteria:
inclusion criteria: available maternal dietary intake data from pregnancy. child turned 7 years by july 1st 2014. exclusion criteria: no maternal baseline questionnaire. maternal energy intake \ 20,000 kj. no dietary supplement data. no linkage to national birth registry, or non-live births, or multiple births. child death, or emigration, or unknown vital status.
epidemiological study of hospitalized children for pulmonary tuberculosis at strasbourg university hospitals

Conditions: Pulmonary Tuberculosis

Summary: pulmonary tuberculosis is the most common form of tuberculosis in children; according to the who, tuberculosis pulmonary tuberculosis in children represents approximately 80% of all cases of tuberculosis in children. in 2020, there were approximately 1.0 million new cases of pulmonary tuberculosis among children worldwide. in france, childhood tuberculosis remains a rare disease; the most recent data show a rate of 3.3 cases per 100,000 inhabitants among children under 15 years old in 2019. pulmonary tuberculosis in children can lead to complications such as bronchiectasis and pneumothorax. children living in homes where an adult has a active tuberculosis, or children with diseases chronic, malnourished or suffering from hiv are more likely to contract tuberculosis. the aim of this research is to determine the incidence, identify the risk factors as well as the clinical forms of pulmonary tuberculosis in children hospitalized at strasbourg university hospitals between 2012 and 2022.


Eligibility criteria:
inclusion criteria: * child (1 to 17 years old) * child hospitalized for pulmonary tuberculosis at strasbourg university hospital between january 1, 2012 and december 31, 2022. * child and/or his/her parental authority who have not expressed their opposition to the reuse of data for scientific research purposes. exclusion criteria: - subject and/or their parental authority having expressed their opposition to the re-use of the child's data for scientific research purposes.

Keywords: pulmonary tuberculosis tuberculosis in children childhood tuberculosis mycobacterium tuberculosis
autonomic dysfunction and inflammation in chronic hemodialysis patients

Conditions: Autonomic Dysfunction; Chronic Renal Failure

Summary: this study investigates the relationship between autonomic dysfunction and chronic inflammation in hemodialysis patients.


Eligibility criteria:
inclusion criteria: * chronic kidney disease stadium kdigo 5d for at leat 3 months on dialysis * age \>18 years * sinus action in ekg * patient capable for informed consent * written and signed informed consent exclusion criteria: * clinical overt signs of infections of any kind * active malign disease * crp levels above 50 mg/l * cardiac pace maker * atrial fibrillation * refusal of informed consent * cardiac transplantation * immunosuppressive medication
the efficacy of everolimus with reduced-dose tacrolimus versus reduced-dose tacrolimus in treatment of bk virus infection in kidney transplantation recipient

Conditions: Kidney Transplant Infection; BK Virus Infection

Summary: bk virus infection is one of the causes of renal allograft loss in the current era. reduction of immunsuppression is the only intervention that prooved to be effective in treating of bk virus in kidney transplant recipient. however, there are evidences from retrospective and prospective studies showed that leflunomide and mtor inhibitor such as everolimus or sirolimus have positive outcomes in treatment of bk virus in kidney tranplant recipient. the investigators conduct the rct to compare the efficacy of leflunomide and mtor inhibitor everolimus, in treatment of bk virus infected patients who do not respond to immunosuppression reduction.


Eligibility criteria:
inclusion criteria: * kidney transplant recipients at king chulalongkorn memorial hospital * age \>= 18 years * persistent bk viremia \>1000 copies/ml at least 2 times in 3 weeks or single time \> 10000 copies/ml exclusion criteria: * bk vl \>10\^5 log * previous bkvan treatment * drug hypersensitivity to mtori or leflunomide

Keywords: kidney transplantation mtor inhibitor leflunomide bk virus
prospective registry of patients over 75 years old treated with xience sierra stents. sierra 75 study

Conditions: Ischemic Heart Disease; Coronary Artery Disease

Summary: this prospective registry is intended to evaluate the safety and efficacy of the xience sierra stent.

this prospective registry is intended to analyze clinical outcomes in elderly patients treated with xience sierra stent and in pre-established subgroups (stable and unstable coronary artery disease).

Eligibility criteria:
inclusion criteria: * age\> 75 years. * with indication of percutaneous revascularization. * presence of de novo coronary artery lesions located in a native coronary artery. * informed consent signed exclusion criteria: * cardiogenic shock at the time of the pci(percutaneous coronary intervention) * cardiac arrest before the pci * life expectancy of the patient under 1 year * participation in another study with a drug or device in clinical research * clinical decision that excludes the use of drug-eluting stents * confirmed allergy to aspirin and / or thienopyridines.

Keywords: dual antiplatelet treatment elderly patients